Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

NCT06390982 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

RECTAL NEOPLASMS
Rectal Cancer

Interventions

RADIATION: Radiotherapy
DRUG: Tislelizumab
DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

Fudan University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]